Chronic renal disease in patients with type 2 diabetes mellitus

Abstract


Diabetes mellitus (DM) type 2 (type 2 diabetes) is one of the most common non-infectious diseases worldwide. Chronic hyperglycemia is a leading factor in a development of vascular complications of diabetes which involve various organs, particularly the eyes, kidney, cardiovascular system and nervous system. One of the most common complications of DM is diabetic nephropathy. Presence of chronic renal disease in a patient with DM limits options of glucose-lowering therapy. Dipeptidyl peptidase-4 inhibitors are currently among medications of choice for glucose-lowering therapy in patients with chronic renal disease. All currently available dipeptidyl peptidase-4 inhibitors can be administrated to patients with end-stage kidney disease on dialysis, and a rate of their use is continuously increasing. Given a high risk of hypoglycemic conditions in patients with chronic renal disease, a regular self-monitoring of glycemia is an essential component of a treatment. Glucometer Contour Plus One is one of the most recent devices developed for self-monitoring of blood glucose. Its advantage over all other blood glucose meters is an ability to synchronize with a mobile application Contour™ Diabetes (Contour Diabetes).

Full Text

Restricted Access

About the authors

Nane E. Khachaturian

A.S.Loginov Moscow Clinical Scientific Practical Center; A.I.Yevdokimov Moscow State University of Medicine and Dentistry

Email: nane18@list.ru
Moscow, Russia

References

  1. Глобальный доклад по диабету ВОЗ, 2016 г.
  2. Mathers C.D, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3 (11): e442.
  3. Шестакова М.В. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных с сахарным диабетом, 2014 г
  4. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. 8-й вып. М., 2017
  5. Betonico C.C, Titan S.M, Correa-Giannella M.L, Nery M et al. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics (Sao Paulo) 2016; 71 (1): 47-53. doi: 10.6061/clinics/2016(01)08
  6. Howse P.M, Chibrikova L.N, Twells L.K et al. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis. Am J Kidney Dis 2016; 68 (5): 733-42. doi: 10.1053/j.ajkd.2016.06.014
  7. Walker S.R, Komenda P, Khojah S et al. Dipep-tidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials. Nephron 2017; 136 (2): 85-94. doi: 10.1159/000454683
  8. Coppolino G, Leporini C, Rivoli L et al. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res 2018; 129: 274-94. doi: 10.1016/j.phrs.2 017.12.001
  9. Милованов Ю.С., Козловская Л.В., Милованова Л.Ю., Шилов Е.М. Проект клинических рекомендаций по питанию больных на додиализных стадиях хронической болезни почек. 2014.
  10. Neisser K, Weber C, Wenzel H, Schneider B. Costs of self-measurement of blood glucose (SMBG) regarding morbidity and mortality in type 2 diabetes in a reality of care setting (The ROSSO study No 6). The European Association for the Study of Diabetes. Abstract Volume 42st Annual Meeting, Copenhagen, Malmoe. 2006; p. 141.
  11. International Organization for Standardization. International Standard EN ISO 15197:2013. In Vitro diagnostic test systems: Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Second Edition 2013-05-15. International Organization for Standardization, 2013.
  12. Контур Плюс. Руководство пользователя. Байер, 2013.

Statistics

Views

Abstract - 5

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies